Lemuteporfin
Lemuteporfin Uses, Dosage, Side Effects, Food Interaction and all others data.
Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.
Trial data accumulated thus far indicate a generally positive tollerability profile and preliminary efficacy.
| Trade Name | Lemuteporfin |
| Generic | Lemuteporfin |
| Lemuteporfin Other Names | Lemuteporfin |
| Type | |
| Formula | C44H48N4O10 |
| Weight | Average: 792.886 Monoisotopic: 792.337043762 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Intended for the treatment of benign prostatic hyperplasia and prostrate disorders.
How Lemuteporfin works
Lemuteporfin is transported in the plasma primarily by lipoproteins. Once lemuteporfin is activated by light in the presence of oxygen, highly reactive, short-lived singlet oxygen and reactive oxygen radicals are generated. Light activation of lemuteporfin results in local damage to neovascular endothelium, resulting in vessel occlusion. Damaged endothelium is known to release procoagulant and vasoactive factors through the lipo-oxygenase (leukotriene) and cyclo-oxygenase (eicosanoids such as thromboxane) pathways, resulting in platelet aggregation, fibrin clot formation and vasoconstriction.
Innovators Monograph
You find simplified version here Lemuteporfin
